T1 Secures Polysilicon 232 Waiver to Import 1.725 GW of Solar Cells for G1_Dallas

What happened

T1 Energy received a Department of Commerce waiver under Section 232 tariffs, permitting import of up to 1.725 GW of solar cells to support uninterrupted production at its G1_Dallas module facility. The waiver aims to alleviate supply constraints amid contracted demand and reinforces T1's position as the largest American-owned manufacturer of TOPCon solar modules. This development mitigates a near-term sourcing risk that had contributed to compliance uncertainty, particularly regarding foreign entity of concern (FEOC) restrictions. However, the waiver does not address the larger overhang: the $510 million G2_Austin cell plant financing remains unresolved, and the company continues to carry elevated related-party sales concentration and liquidity pressures. As such, the operational relief is positive but insufficient to alter the fundamental thesis until G2 funding and execution are clarified.

Implication

Investors should treat this waiver as a tactical positive that secures module production continuity but not a strategic catalyst. The core challenge persists: T1 must close comprehensive financing for G2_Austin Phase 1 without excessive dilution, and recent capex inflation and timeline slips have raised execution risk. Revenue quality remains weak due to heavy related-party dependence, and near-term cash needs from Evervolt obligations and operating losses are not resolved by this waiver. Monitor third-quarter results for evidence of improved third-party sales and liquidity, as well as any progress on G2 financing. No change to positioning is warranted; maintain a cautious stance and only consider adding if a credible funding package is filed.

Thesis delta

The waiver modestly strengthens the operational case by lowering supply-chain disruption risk and supporting near-term contracted revenue at G1_Dallas. However, it does not address the primary investment concern: securing and executing G2_Austin financing without significant dilution. Therefore, the overall thesis remains unchanged, with the stock still rated WAIT pending financing clarity and execution milestones.